Last updated: September 6, 2026
Ibrexafungerp citrate, marketed as Brexafemme by SCYNEXIS, is an oral, non-azole antifungal approved in the United States for vulvovaginal candidiasis and for reducing recurrent vulvovaginal candidiasis. Its commercial value depends on differentiation from fluconazole, treatment of azole-resistant infections, use in patients who cannot take azoles, and expansion into invasive fungal disease. Product revenue rose sharply after launch but remains constrained by a concentrated indication, payer control, and competition from inexpensive generic antifungals.
What is ibrexafungerp citrate and how is Brexafemme positioned?
Ibrexafungerp is a triterpenoid antifungal that inhibits glucan synthase, the same fungal target class affected by echinocandins. Unlike intravenous echinocandins, ibrexafungerp is orally administered. Unlike fluconazole and other azoles, it does not rely on the same mechanism or chemical class.
The FDA approved Brexafemme in June 2021 for acute vulvovaginal candidiasis in adult and postmenarchal pediatric females. In December 2022, the FDA expanded the label to include reduction in the incidence of recurrent vulvovaginal candidiasis in adult and postmenarchal pediatric females with a history of recurrent disease. The recurrent-disease regimen is administered monthly for six months following treatment of the initial infection.[1]
| Attribute |
Ibrexafungerp citrate |
| Brand |
Brexafemme |
| Developer and U.S. commercializer |
SCYNEXIS |
| Drug class |
Triterpenoid antifungal |
| Route |
Oral |
| Initial FDA approval |
June 2021 |
| Additional FDA approval |
December 2022 |
| Acute indication |
Vulvovaginal candidiasis |
| Recurrence indication |
Reduction of recurrent vulvovaginal candidiasis |
| Principal differentiation |
Non-azole mechanism with oral dosing |
| Generic status |
No approved generic reported through the public filings reviewed |
| Biosimilar risk |
Not applicable to this small-molecule drug |
The product’s strategic positioning is strongest in patients with azole intolerance, drug-interaction concerns, recurrent disease, or suspected azole resistance. The commercial challenge is that many uncomplicated infections remain treatable with low-cost generic fluconazole.
How large is the market for ibrexafungerp?
The addressable market is large in patient volume but narrower in revenue opportunity. Vulvovaginal candidiasis is common, yet standard therapy is inexpensive and often prescribed generically. Brexafemme therefore competes for selected prescriptions rather than the entire candidiasis market.
The main market segments are:
- Acute vulvovaginal candidiasis.
- Recurrent vulvovaginal candidiasis requiring preventive therapy.
- Patients who cannot use azoles because of resistance, intolerance, pregnancy-related restrictions, or drug interactions.
- Potential future use in invasive candidiasis and other serious fungal infections.
The recurrent-disease indication has greater commercial value per treated patient than single-episode therapy because it creates repeated monthly dosing and a longer treatment duration. It also gives SCYNEXIS a basis for direct engagement with gynecologists, women’s-health providers, and managed-care organizations.
The commercial ceiling remains limited by four factors:
- Fluconazole and topical azoles are widely available as generics.
- Many patients receive episodic rather than preventive treatment.
- Payers can require prior authorization or step therapy.
- Brexafemme is an oral prescription product for a condition that physicians often treat in primary care or urgent-care settings.
What has been the financial trajectory of Brexafemme?
SCYNEXIS reported a steep increase in commercial revenue after the 2021 launch. Public filings indicate that product revenue increased from a low post-launch base in 2022 to approximately $48 million in 2023, although reported revenue can include collaboration, milestone, or other commercial components depending on the reporting period.[2]
| Period |
Financial trend |
Commercial interpretation |
| 2021 |
Initial U.S. launch |
Limited launch-year contribution |
| 2022 |
Revenue increased after market access expansion |
Acute indication plus preparation for recurrent-disease launch |
| 2023 |
Approximately $48 million in reported revenue |
Meaningful commercial scale, but still loss-making at company level |
| 2024 onward |
Dependent on recurrent-disease adoption and broader antifungal development |
Greater value requires indication expansion or strategic transaction |
SCYNEXIS continued to report operating losses despite revenue growth because it remained responsible for commercial infrastructure, medical affairs, research and development, regulatory work, manufacturing commitments, and debt or financing costs. Brexafemme’s gross margin can be attractive as an oral small molecule, but profitability depends on prescription volume and the cost of customer acquisition.
Revenue quality is also important. Acute vulvovaginal candidiasis generates a one-time prescription, while recurrent-disease therapy can generate six months of treatment. Growth in the recurrent indication is therefore more valuable than equivalent growth in acute prescriptions.
What are the main commercial drivers for ibrexafungerp?
Recurrent vulvovaginal candidiasis
The recurrent-disease indication is the primary commercial expansion mechanism. It increases duration of therapy and gives the company access to patients for whom repeated fluconazole treatment may be ineffective, poorly tolerated, or clinically undesirable.
The indication also supports a more differentiated payer and physician message than the acute indication. Prevention of recurrence can reduce repeated office visits, diagnostic testing, and short-course prescriptions, although payers may still compare the product with inexpensive generic alternatives.
Azole resistance and intolerance
Ibrexafungerp’s non-azole mechanism is its central product advantage. Candida species with reduced azole susceptibility can create a treatment gap. The size of that opportunity is smaller than the general candidiasis market, but treatment choice is more clinically consequential and price sensitivity may be lower.
Drug-interaction profile
Azoles are associated with cytochrome P450 interactions and other prescribing limitations. Brexafemme is not interaction-free, however. The FDA label includes warnings involving pregnancy and drug interactions, including interactions affecting exposure to ibrexafungerp.[1] These label restrictions can reduce use in some patients while increasing its relevance in others.
Prescriber familiarity
Fluconazole has decades of clinical use. Ibrexafungerp must overcome physician familiarity, institutional protocols, payer controls, and patient expectations that uncomplicated candidiasis should be treated with a low-cost generic.
How does ibrexafungerp compare with fluconazole and other antifungals?
| Factor |
Ibrexafungerp |
Fluconazole |
Topical azoles |
Echinocandins |
| Route |
Oral |
Oral |
Vaginal or topical |
Intravenous |
| Mechanism |
Glucan synthase inhibition |
Azole antifungal |
Azole antifungal |
Glucan synthase inhibition |
| Generic competition |
No established generic competition reported |
Extensive |
Extensive |
Multiple products |
| Use in recurrent VVC |
Approved prevention indication |
Commonly used off-label or under established practice |
Used in selected patients |
Not practical for routine VVC |
| Resistance differentiation |
Potential advantage in azole-resistant disease |
Weaker where azole resistance exists |
Weaker where azole resistance exists |
Strong, but unsuitable for routine outpatient use |
| Cost position |
Premium branded therapy |
Low-cost generic |
Low-cost generic |
High-cost institutional therapy |
| Commercial weakness |
Limited indication and payer scrutiny |
Low price and high familiarity |
Low price and local administration |
Intravenous administration |
Brexafemme is not a direct replacement for every fluconazole prescription. Its most defensible market position is as an alternative for selected patients and as a preventive therapy for recurrent disease.
What patent and regulatory protections cover Brexafemme?
Brexafemme benefits from FDA approval, regulatory exclusivity, and listed patent protection. The initial five-year new chemical entity exclusivity period associated with a 2021 approval would generally extend into 2026, subject to the precise regulatory calculation and any pediatric exclusivity adjustment. The 2022 supplemental approval did not create a new five-year chemical-entity exclusivity period.
The product’s patent strategy is more important than regulatory exclusivity because a small-molecule product can face abbreviated new drug application competition after statutory exclusivity expires. SCYNEXIS has disclosed patent protection covering ibrexafungerp and related pharmaceutical compositions. The commercial value of those patents depends on whether an ANDA applicant can avoid the listed claims through a Paragraph IV certification or delay launch until expiration.
Key protection categories include:
- The active compound and related chemical entities.
- Pharmaceutical compositions and oral dosage forms.
- Treatment of vulvovaginal candidiasis.
- Prevention or reduction of recurrent infection.
- Dosing regimens and administration schedules.
- Potential use in invasive fungal infections.
The Orange Book status must be assessed against the current FDA listing because patent additions, delistings, pediatric exclusivity, and litigation events can change the practical generic-entry date.[3] A composition or formulation patent that expires later than the basic compound patent can materially extend protection if its claims are difficult to design around.
When could generic ibrexafungerp enter the U.S. market?
Generic-entry risk is likely to increase after the core regulatory exclusivity period and as key listed patents approach expiration. The earliest practical launch date depends on:
- The expiration of FDA exclusivity.
- The expiration or invalidation of Orange Book-listed patents.
- The date an ANDA applicant files a Paragraph IV certification.
- Whether SCYNEXIS sues within the statutory 45-day period.
- The resulting 30-month stay or any earlier court decision.
- The scope of any settlement agreement.
A generic applicant could challenge a composition patent, formulation patent, or method-of-use patent. Method-of-use patents can be less effective against a broad market if an ANDA label omits the patented use, but they may still matter when the principal commercial indication is the protected use.
No broad biosimilar pathway applies. Ibrexafungerp is a chemically synthesized small molecule, so the relevant competitive pathway is the ANDA process, not a biosimilar application under the Public Health Service Act.
Which companies are challenging or competing with ibrexafungerp?
The competitive field is fragmented rather than concentrated around one branded rival.
Generic fluconazole manufacturers
Teva, Viatris, Sandoz, Amneal, Rising Pharmaceuticals, and other generic manufacturers supply fluconazole in the United States. These products establish a low-price benchmark that limits Brexafemme’s ability to compete for routine cases.
Branded and generic topical antifungals
Terconazole, clotrimazole, miconazole, and related products compete for patients who prefer local therapy or whose clinicians seek to avoid systemic exposure.
Emerging antifungal developers
Other developers are pursuing oral or long-acting agents for resistant fungal infections. Their direct effect on Brexafemme depends on whether they target vulvovaginal candidiasis, invasive candidiasis, or hospital-based fungal disease.
Pfizer and conventional hospital antifungals
Pfizer and other large antifungal suppliers are more relevant to invasive candidiasis than to routine vulvovaginal candidiasis. Their products compete with the broader ibrexafungerp pipeline opportunity rather than with Brexafemme’s core outpatient indication.
What litigation and licensing issues affect ibrexafungerp?
The most important legal risk is a future ANDA Paragraph IV challenge. A patent dispute could occur before or after regulatory exclusivity expires. The outcome would determine whether a generic launches at risk, waits for patent expiration, or reaches a settlement with SCYNEXIS.
Licensing and strategic-partner economics also affect the asset’s value. SCYNEXIS has historically used collaborations and external financing to support development and commercialization. A transaction or licensing deal could improve distribution and reduce commercialization costs, but it could also transfer a portion of future Brexafemme economics to a partner.
The commercial asset is more valuable to a company with an established women’s-health or infectious-disease sales force than to a small biotechnology company that must fund broad commercial coverage independently.
How strong is the ibrexafungerp commercial and patent estate?
The commercial estate is moderately differentiated but not fully insulated. Its strengths are:
- FDA approval in two clinically distinct indications.
- Oral dosing for a mechanism associated with echinocandin activity.
- Potential use in azole-resistant or azole-intolerant patients.
- A recurrent-disease indication with longer treatment duration.
- Possible expansion into invasive fungal infections.
Its weaknesses are:
- Strong generic competition from fluconazole and topical azoles.
- Limited number of approved indications.
- Payer pressure on a premium product.
- Need for continued clinical investment.
- Potential ANDA challenges after core exclusivity expires.
- Dependence on provider awareness and diagnostic confirmation.
The patent estate is strongest if compound and formulation claims remain enforceable through the period when Brexafemme reaches peak revenue. It is weaker if the commercial value rests mainly on method-of-use claims that can be avoided through a narrow generic label.
What is the outlook for ibrexafungerp revenue?
The base-case trajectory is continued growth from the post-launch revenue base, with the recurrent-vulvovaginal-candidiasis indication contributing higher-value prescriptions. Growth is likely to moderate as the product reaches more commercially accessible prescribers and faces payer controls.
The upside case depends on three developments:
- Strong adoption of monthly prevention therapy.
- Broader use in azole-resistant or azole-intolerant infections.
- Positive clinical and regulatory outcomes in invasive candidiasis or other serious fungal infections.
The downside case involves limited recurrent-disease uptake, payer restrictions, lower-than-expected persistence, and accelerated generic competition. Without a second major indication, Brexafemme is more likely to remain a specialty commercial product than become a broad antifungal franchise.
Key Takeaways
- Ibrexafungerp citrate is the active ingredient in Brexafemme, an oral non-azole antifungal.
- FDA approvals cover acute vulvovaginal candidiasis and reduction of recurrent disease.
- Reported revenue increased to approximately $48 million in 2023 from a smaller 2022 base.
- The recurrent-disease indication is the principal driver of prescription durability and revenue per patient.
- Generic fluconazole and topical azoles remain the main commercial barriers.
- Biosimilar risk does not apply; future competition will proceed through the ANDA pathway.
- Patent and Orange Book analysis will determine the effective generic-entry date.
- The greatest valuation upside depends on expansion into invasive fungal disease or other high-value indications.
- The asset has meaningful differentiation but remains exposed to payer controls, low-cost generics, and a limited initial market.
FAQs About Ibrexafungerp Citrate
Is ibrexafungerp citrate the same as Brexafemme?
Yes. Ibrexafungerp citrate is the active pharmaceutical ingredient in Brexafemme tablets.
Is Brexafemme stronger than fluconazole?
The products have different mechanisms. Brexafemme may provide a clinical option when azoles are unsuitable or less effective, but it is not universally superior for uncomplicated infection.
Can ibrexafungerp be used for invasive candidiasis?
Ibrexafungerp has been developed for broader antifungal use, including invasive disease, but commercial use depends on the applicable FDA-approved indication and label.
Why is ibrexafungerp commercially important if fluconazole is generic?
Its value comes from non-azole activity, oral administration, recurrent-disease prevention, and potential use in patients with resistance, intolerance, or drug-interaction concerns.
What is the principal investment risk for Brexafemme?
The principal risk is that adoption remains concentrated in selected patients while low-cost generic antifungals limit pricing, volume, and payer coverage.
References
-
U.S. Food and Drug Administration. (2023). Brexafemme (ibrexafungerp tablets) prescribing information. FDA.
-
SCYNEXIS, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
